Tags : MACE events

Regeneron and Sanofi Reports Results of Praluent (alirocumab) in ODYSSEY

Vartika Singh November 12, 2018

Shots: The study involves assessing of Praluent (75mg & 150mg, q2w) vs PBO in patients with MACE events and experienced ACS between 1 to 12 mos. in 18,924 patients for […]readmore

Regulatory

Janssen’s (J&J) Invokana (canagliflozin) Receives FDA Approval for MACE events

Vartika Singh October 31, 2018

Shots: The approval is based on the results of CANVAS (CANagliflozin cardioVascular Assessment Study) Program assessing Invokana vs PBO + SoC in 10,000 adults having or at risk CV disease […]readmore

Tags : MACE events

Regeneron and Sanofi Reports Results of Praluent (alirocumab) in ODYSSEY

Janssen’s (J&J) Invokana (canagliflozin) Receives FDA Approval for MACE events

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : MACE events

Regeneron and Sanofi Reports Results of Praluent (alirocumab) in ODYSSEY

Janssen’s (J&J) Invokana (canagliflozin) Receives FDA Approval for MACE events

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company